Dr. Elisabeth I Heath, MD
Claim this profileKarmanos Cancer Institute
Expert in Prostate Cancer
Studies Cancer
18 reported clinical trials
40 drugs studied
Area of expertise
1Prostate Cancer
Global LeaderStage IV
CDK12 positive
MET positive
2Cancer
Stage IV
HER2 positive
Stage III
Affiliated Hospitals
Clinical Trials Elisabeth I Heath, MD is currently running
Standard Therapy + Surgery/Radiation
for Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting2 awards Phase 330 criteria
Cabozantinib +/− Atezolizumab
for Advanced Kidney Cancer
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of cancer cells. Combination therapy with atezolizumab and cabozantinib may shrink the cancer and allow a longer survival time in patients with metastatic renal cell carcinoma.
Recruiting1 award Phase 230 criteria
More about Elisabeth I Heath, MD
Clinical Trial Related3 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Elisabeth I Heath, MD has experience with
- Prednisone
- Nivolumab
- Ipilimumab
- Sitravatinib
- SGN1
- CCW702
Breakdown of trials Elisabeth I Heath, MD has run
Prostate Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Elisabeth I Heath, MD specialize in?
Elisabeth I Heath, MD focuses on Prostate Cancer and Cancer. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are CDK12 positive.
Is Elisabeth I Heath, MD currently recruiting for clinical trials?
Yes, Elisabeth I Heath, MD is currently recruiting for 11 clinical trials in Detroit Michigan. If you're interested in participating, you should apply.
Are there any treatments that Elisabeth I Heath, MD has studied deeply?
Yes, Elisabeth I Heath, MD has studied treatments such as Prednisone, Nivolumab, Ipilimumab.
What is the best way to schedule an appointment with Elisabeth I Heath, MD?
Apply for one of the trials that Elisabeth I Heath, MD is conducting.
What is the office address of Elisabeth I Heath, MD?
The office of Elisabeth I Heath, MD is located at: Karmanos Cancer Institute, Detroit, Michigan 48201 United States. This is the address for their practice at the Karmanos Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.